| BioMOx BioMOx: The Oxford Study for Biomarkers in Motor Neuron Disease | 2018-12-31 | • Data being analysed;
• Manuscript in preparation;
• Results published (links to papers provided). |
| Tongue EIM Developing electrical impedance myography of the tongue for motor system disorders | 2018-07-31 | Closed to Recruitment, In Follow Up |
| Biogen Methodology study Methodology Study of Novel Outcome Measures to Assess Progression of ALS | 2017-05-31 | Analysis |
| ALS/FTD study Is ALS/FTD Neuropsychologically distinct from FTD? | 2017-10-15 | Closed to Recruitment, No Follow Up |
| CALL-Me Assessment of care augmentation by location-linked messaging in amyotrophic lateral sclerosis with respiratory impairment compared with current standard care | 2019-02-07 | Closed to Recruitment, In Follow Up |
| OPTCARE Neuro Evaluation of the clinical and cost effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced longterm Neurological conditions (OPTCARE Neuro) | 2017-11-10 | Closed to Recruitment, In Follow Up |
| ALSCarE A Programme for ALS Care in Europe (ALSCarE) | 2017-08-04 | Closed to Recruitment, In Follow Up |
| EncoreAnywhere Monitoring and promoting adherence to non-invasive ventilation in motor neurone disease using EncoreAnywhere telemonitoring | 2017-04-01 | Closed to Recruitment, In Follow Up |
| CSNAT Enabling tailored and coordinated support for family carers of people with Motor Neurone Disease (MND) through adaptation of a Carer Support Needs Assessment Tool (CSNAT) Intervention | 2019-06-17 | Closed to Recruitment, no follow up |
| COMMEND feasibility study A feasibility study of acceptance and COMmitment therapy for people with Motor nEuroN Disease (COMMEND) | 2018-11-30 | Closed to Recruitment, In Follow Up |
| Using MRI to investigate energy metabolism Using MRI to investigate energy metabolism | | Closed to Recruitment, no follow up |
| MIROCALS Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placebo- controlled, phase-II Proof of Concept/ Proof of Mechanism Clinical Trial | 2019-11-04 | Closed to Recruitment, In Follow Up |